Amedisys Reports Second Quarter Financial Results

  Amedisys Reports Second Quarter Financial Results

           Amedisys to Host Conference Call Today at 10:00 a.m. ET

Business Wire

BATON ROUGE, La. -- July 31, 2013

Amedisys, Inc. (NASDAQ: AMED), a leading home health and hospice company,
today reported its financial results for the second quarter ended June30,
2013.

Three-Month Periods Ended June30, 2013 and 2012

  *After adding back $5.1 million and $1.4 million ($3.1 million and $0.8
    million, net of income tax) or $0.10 and $0.03 per diluted share for exit
    activity costs, the gain on sale of care centers and legal fees associated
    with investigations, the following would have been our adjusted results:

       *Net service revenue of $313.1 million compared to $363.1 million in
         2012, a decrease of 13.7%.
       *Net income from continuing operations attributable to Amedisys, Inc.,
         of $5.4 million compared to $8.7 million in 2012, a decrease of
         38.0%.
       *Net income from continuing operations attributable to Amedisys, Inc.
         per diluted share of $0.17 compared to $0.29 per diluted share in
         2012, a decrease of 41.4%.
       *Earnings before interest, taxes, depreciation and amortization
         attributable to continuing operations (“EBITDA”) of $19.1 million
         compared to $26.6 million in 2012, a decrease of 28.3%.

Six-Month Periods Ended June30, 2013 and 2012

  *After adding back $7.1 million and $5.1 million ($4.3 million and $3.0
    million, net of income tax) or $0.14 and $0.10 per diluted share for exit
    activity costs, the gain on sale of care centers and legal fees associated
    with investigations, the following would have been our adjusted results:

       *Net service revenue of $639.2 million compared to $719.0 million in
         2012, a decrease of 11.1%.
       *Net income from continuing operations attributable to Amedisys, Inc.,
         of $9.8 million compared to $17.7 million in 2012, a decrease of
         44.7%.
       *Net income from continuing operations attributable to Amedisys, Inc.
         per diluted share of $0.31 compared to $0.59 per diluted share in
         2012, a decrease of 47.5%.
       *EBITDA of $37.0 million compared to $53.9 million in 2012, a decrease
         of 31.4%.

William F. Borne, Chief Executive Officer stated, “We are pleased to report
adjusted earnings for the second quarter of $0.17 per share, an improvement of
$0.03 sequentially. Despite a $0.09 negative impact from sequestration and
continued lower volumes, reductions in operating expenses led to the improved
results. We continue to make progress on numerous strategic initiatives
focused on growth, increasing efficiency and continued improvement in patient
outcomes.”

2013 Guidance

  *Net service revenue is anticipated to be in the range of $1.240 billion to
    $1.280 billion.
  *Diluted earnings per share is expected to be in the range of $0.45 to
    $0.55 based on an estimated 31.5 million shares outstanding.

This guidance excludes any one-time costs associated with our announced market
exit activity or corporate expense initiatives. Our guidance includes an
estimate of legal costs associated with our on-going government
investigations.

We urge caution in considering the current trends and 2013 guidance disclosed
in this press release. The home health and hospice industry is highly
competitive and subject to intensive regulations, and trends and guidance are
subject to numerous factors, risks, and uncertainties, some of which are
referenced in the cautionary language below and others that are described more
fully in our reports filed with the Securities and Exchange Commission (“SEC”)
including our Annual Report on Form 10-K for the fiscal year ended December
31, 2012, and subsequent Quarterly Reports on Form 10-Q, and current reports
on Form 8-K which can be found on the SEC’s internet website,
http://www.sec.gov, and our internet website, http://www.amedisys.com. We
disclaim any obligations to update disclosed information on trends.

* See page 8 for the reconciliations of non-GAAP financial measures

Earnings Call and Webcast Information

To participate in the conference call, please call a few minutes before 10:00
a.m. ET on Wednesday, July31, 2013, to either (877)512-9171 (Toll free) or
(815)573-0979 (Toll), use conference ID #22419959. A replay of the conference
call will be available through August7, 2013. The replay dial in number is
(855)859-2056 (Toll free) or (404)537-3406 (Toll), use conference ID
#22419959.

The call will also be available through our website and for seven days
thereafter at the following web address: http://investors.amedisys.com.

We are headquartered in Baton Rouge, Louisiana. Our common stock trades on the
NASDAQ Global Select Market under the symbol “AMED.”

Additional information

Our company website address is www.amedisys.com. We use our website as a
channel of distribution for important company information. Important
information, including press releases, analyst presentations and financial
information regarding our company, is routinely posted on and accessible on
the Investor Relations subpage of our website, which is accessible by clicking
on the tab labeled “Investors” on our website home page. We also use our
website to expedite public access to time-critical information regarding our
company in advance of or in lieu of distributing a press release or a filing
with the SEC disclosing the same information. Therefore, investors should look
to the Investor Relations subpage of our website for important and
time-critical information. Visitors to our website can also register to
receive automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations subpage of our
website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,”
“expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,”
“might,” “would,” “should” and similar expressions are intended to identify
forward-looking statements as defined by the Private Securities Litigation
Reform Act of 1995. These forward-looking statements involve a variety of
risks and uncertainties that could cause actual results to differ materially
from those described therein. These risks and uncertainties include, but are
not limited to the following: changes in Medicare and other medical payment
levels, our ability to open care centers, acquire additional care centers and
integrate and operate these care centers effectively, our ability to divest
care centers currently held for sale, changes in or our failure to comply with
existing Federal and State laws or regulations or the inability to comply with
new government regulations on a timely basis, competition in the home health
industry, changes in the case mix of patients and payment methodologies,
changes in estimates and judgments associated with critical accounting
policies, our ability to maintain or establish new patient referral sources,
our ability to attract and retain qualified personnel, changes in payments and
covered services due to the economic downturn and deficit spending by Federal
and State governments, future cost containment initiatives undertaken by
third-party payors, our access to financing due to the volatility and
disruption of the capital and credit markets, our ability to meet debt service
requirements and comply with covenants in debt agreements, business
disruptions due to natural disasters or acts of terrorism, our ability to
integrate and manage our information systems, changes in or developments with
respect to any litigation or investigations relating to the Company, including
the SEC investigation and the U.S. Department of Justice Civil Investigative
Demand and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified, you should not
rely on any forward-looking statement as a prediction of future events. We
expressly disclaim any obligation or undertaking and we do not intend to
release publicly any updates or changes in our expectations concerning the
forward-looking statements or any changes in events, conditions or
circumstances upon which any forward-looking statement may be based, except as
required by law.

Non-GAAP Financial Measures

This press release includes the following non-GAAP financial measures as
defined under SEC rules: EBITDA, defined as net income from continuing
operations attributable to Amedisys, Inc. before provision for income taxes,
net interest expense and depreciation and amortization, adjusted EBITDA,
defined as EBITDA plus exit activity costs, the gain on sale of care centers
and legal fees associated with investigations, adjusted net income from
continuing operations attributable to Amedisys, Inc., defined as net income
from continuing operations attributable to Amedisys, Inc. plus exit activity
costs, the gain on sale of care centers and legal fees associated with
investigations, and adjusted net income from continuing operations
attributable to Amedisys, Inc. per diluted share, defined as net income from
continuing operations attributable to Amedisys, Inc. common stockholders per
diluted share plus the earnings per share effect of exit activity costs, the
gain on sale of care centers and legal fees associated with investigations. In
accordance with SEC rules, we have provided herein a reconciliation of these
non-GAAP financial measures to the most directly comparable measures under
GAAP. Management believes that these are useful gauges of our performance and
are common measures used in our industry to assess relative financial
performance among companies.






AMEDISYS, INC. AND SUBSIDIARIES
SELECT CONSOLIDATED FINANCIAL STATEMENT DATA AND SUPPLEMENTAL INFORMATION
(Amounts in thousands, except share, per share data and statistical
information)
(Unaudited)

Balance Sheet Information

                                            June 30, 2013  December 31, 2012
ASSETS
Current assets:
Cash and cash equivalents                    $  30,118       $   14,545
Patient accounts receivable, net of
allowance for doubtful accounts of $17,610      124,766          169,172
and $20,994
Prepaid expenses                                13,369           10,631
Other current assets                            12,006           11,440
Assets held for sale                           1,550          —         
                                                             
Total current assets                            181,809          205,788
Property and equipment, net of accumulated      156,887          156,709
depreciation of $120,012, and $113,154
Goodwill                                        209,260          209,594
Intangible assets, net of accumulated           43,109           47,050
amortization of $24,560 and $23,457
Deferred tax asset                              85,256           92,804
Other assets, net                              23,932         18,650    
                                                             
Total assets                                 $  700,253     $   730,595   
                                                             
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable                             $  21,658       $   29,175
Payroll and employee benefits                   76,205           79,341
Accrued expenses                                54,175           54,855
Current portion of long-term obligations        35,807           35,807
Current portion of deferred income taxes       3,169          5,609     
                                                             
Total current liabilities                       191,014          204,787
Long-term obligations, less current             39,000           66,904
portion
Other long-term obligations                    5,209          4,671     
                                                             
Total liabilities                              235,223        276,362   
                                                             
Equity:
Preferred stock, $0.001 par value,
5,000,000 shares authorized; none issued        —                —
or outstanding
Common stock, $0.001 par value, 60,000,000
shares authorized; 32,973,576 and               33               32
31,876,508 share issued; and 32,106,174
and 31,086,619 share outstanding
Additional paid-in capital                      458,475          450,792
Treasury stock at cost, 867,402 and             (18,056  )       (17,116   )
789,889 shares of common stock
Accumulated other comprehensive income          15               15
Retained earnings                              23,136         18,617    
                                                             
Total Amedisys, Inc. stockholders’ equity       463,603          452,340
Noncontrolling interests                       1,427          1,893     
                                                             
Total equity                                   465,030        454,233   
                                                             
Total liabilities and equity                 $  700,253     $   730,595   






Income Statement Information

                  For the Three-Month Periods        For the Six-Month Periods
                 Ended                             Ended
                  June 30,                           June 30,
                  2013             2012             2013         2012
Net service       $  313,148        $  363,068       $ 639,201     $ 719,056
revenue
Cost of
service,
excluding            176,077           202,586         360,233       401,637
depreciation
and
amortization
General and
administrative
expenses:
Salaries and         74,601            82,983          154,043       166,270
benefits
Non-cash             1,224             2,298           3,280         4,780
compensation
Other                41,121            45,632          82,739        88,240
Provision for
doubtful             4,658             4,534           8,502         10,217
accounts
Depreciation
and                 11,674          9,678         21,621      19,515  
amortization
                                                                   
Operating           309,355         347,711       630,418     690,659 
expenses
                                                                   
Operating            3,793             15,357          8,783         28,397
income
Other (expense)
income:
Interest income      11                28              22            42
Interest             (730     )        (2,002   )      (1,836  )     (4,076  )
expense
Equity in
earnings from        337               396             700           701
equity
investments
Gain on sale of      357               —               357           —
care centers
Miscellaneous,      136             (126     )     196         309     
net
                                                                   
Total other         111             (1,704   )     (561    )    (3,024  )
expense, net
                                                                   
Income before        3,904             13,653          8,222         25,373
income taxes
Income tax          (1,566   )       (5,666   )     (3,260  )    (10,530 )
expense
                                                                   
Income from
continuing           2,338             7,987           4,962         14,843
operations
Discontinued
operations, net     (490     )       (21      )     (982    )    (1,414  )
of tax
                                                                   
Net income           1,848             7,966           3,980         13,429
Net (income)
loss
attributable to     (7       )       (84      )     539         (127    )
noncontrolling
interests
                                                                   
Net income
attributable to   $  1,841         $  7,882        $ 4,519      $ 13,302  
Amedisys, Inc.
                                                                   
Basic earnings
per common
share:
Income from
continuing
operations
attributable to   $  0.07           $  0.26          $ 0.18        $ 0.50
Amedisys, Inc.
common
stockholders
Discontinued
operations, net     (0.01    )       —             (0.03   )    (0.05   )
of tax
                                                                   
Net income
attributable to
Amedisys, Inc.    $  0.06          $  0.26         $ 0.15       $ 0.45    
common
stockholders
                                                                   
Weighted
average shares      31,160          29,780        30,900      29,584  
outstanding
                                                                   
Diluted
earnings per
common share:
Income from
continuing
operations
attributable to   $  0.07           $  0.26          $ 0.17        $ 0.49
Amedisys, Inc.
common
stockholders
Discontinued
operations, net     (0.01    )       —             (0.03   )    (0.05   )
of tax
                                                                   
Net income
attributable to
Amedisys, Inc.    $  0.06          $  0.26         $ 0.14       $ 0.44    
common
stockholders
                                                                   
Weighted
average shares      31,489          30,026        31,298      29,903  
outstanding
                                                                   
Amounts
attributable to
Amedisys, Inc.
common
stockholders:
Income from
continuing        $  2,331          $  7,903         $ 5,501       $ 14,716
operations
Discontinued
operations, net     (490     )       (21      )     (982    )    (1,414  )
of tax
                                                                   
Net income        $  1,841         $  7,882        $ 4,519      $ 13,302  






Cash Flow and Days Revenue Outstanding, Net Information

                 For the Three-Month Periods        For the Six-Month Periods
                ended                             ended
                 June 30,                           June 30,
                 2013            2012              2013          2012
Net cash
provided by      $  33,561        $  21,178         $  65,977      $ 32,105
operating
activities
Net cash used
in investing        (7,390  )        (17,878  )        (24,215 )     (27,931 )
activities
Net cash used
in financing       (3,074  )       (7,432   )       (26,189 )    (15,020 )
activities
                                                                   
Net increase
(decrease) in       23,097           (4,132   )        15,573        (10,846 )
cash and cash
equivalents
Cash and cash
equivalents        7,021          41,290          14,545      48,004  
at beginning
of period
                                                                   
Cash and cash
equivalents      $  30,118       $  37,158        $  30,118     $ 37,158  
at end of
period
                                                                   
Days revenue
outstanding,        33.9             38.0              33.9          38.0
net (1)

(1) Our calculation of days revenue outstanding, net at June30, 2013 and 2012
is derived by dividing our ending patient accounts receivable (i.e., net of
estimated revenue adjustments and allowance for doubtful accounts) by our
average daily net patient revenue for the three month-period ended June30,
2013 and 2012, respectively.





Supplemental Information - Home Health

                              For the Three-Month Periods Ended June 30,
                               2013                        2012
Financial Information (in
millions):
Medicare                       $    202.9                   $   229.4
Non-Medicare                       45.7                      61.2       
                                                            
Net service revenue                 248.6                       290.6
Cost of service                    142.0                     165.3      
                                                            
Gross margin                        106.6                       125.3
Other operating expenses           81.2                      88.8       
                                                            
Operating income               $    25.4                   $   36.5       
                                                            
Key Statistical Data:
Medicare:
Same Store Volume (1)
Revenue                             (10          %)             (8         %)
Admissions                          0            %              2          %
Recertifications                    (18          %)             (7         %)
Total:
Admissions                          47,381                      48,023
Recertifications                    27,331                      33,965
Completed Episodes                  74,963                      79,781
Visits                              1,312,222                   1,546,329
Average revenue per            $    2,828                   $   2,879
completed episode (2)
Visits per completed                17.6                        19.1
episode (3)
Non-Medicare:
Admissions                          18,161                      23,047
Recertifications                    7,516                       10,465
Visits                              378,928                     523,111
Total:
Cost per Visit                 $    83.98                   $   79.86
Visits                              1,691,150                   2,069,440




                               For the Six-Month Periods Ended June 30,
                               2013                         2012
Financial Information (in
millions):
Medicare                       $    413.9                   $   460.7
Non-Medicare                       94.9                      117.7      
                                                            
Net service revenue                 508.8                       578.4
Cost of service                    291.3                     328.5      
                                                            
Gross margin                        217.5                       249.9
Other operating expenses           165.4                     181.0      
                                                            
Operating income               $    52.1                   $   68.9       
                                                            
Key Statistical Data:
Medicare:
Same Store Volume (1)
Revenue                             (9           %)             (8         %)
Admissions                          1            %              0          %
Recertifications                    (17          %)             (6         %)
Total:
Admissions                          97,047                      96,767
Recertifications                    55,836                      68,328
Completed Episodes                  150,362                     158,352
Visits                              2,671,801                   3,099,753
Average revenue per            $    2,801                   $   2,876
completed episode (2)
Visits per completed                17.5                        18.9
episode (3)
Non-Medicare:
Admissions                          39,699                      45,333
Recertifications                    15,707                      19,942
Visits                              800,086                     1,008,690
Total:
Cost per Visit                 $    83.90                   $   79.95
Visits                              3,471,887                   4,108,443

(1) Medicare revenue, admissions or recertifications volume is the percent
increase (decrease) in our Medicare revenue, admissions or recertifications
for the period as a percent of the Medicare revenue, admissions or
recertifications of the prior period.

(2)Average Medicare revenue per completed episode is the average Medicare
revenue earned for each Medicare completed episode of care which excludes the
impact of sequestration.

(3)Medicare visits per completed episode are the home health Medicare visits
on completed episodes divided by the home health Medicare episodes completed
during the period.






Supplemental Information - Hospice

                           For the Three-Month Periods Ended June 30,
                            2013                         2012
Financial Information
(in millions):
Medicare                    $     60.8                    $     68.7
Non-Medicare                     3.7                         3.8       
                                                          
Net service revenue               64.5                          72.5
Cost of service                  34.1                        37.3      
                                                          
Gross margin                      30.4                          35.2
Other operating                  17.7                        18.7      
expenses
                                                          
Operating income            $     12.7                   $     16.5      
                                                          
Key Statistical Data:
Same store Medicare               (12        %)                 22        %
revenue growth (1)
Hospice Admits                    4,600                         4,797
Average daily census              4,939                         5,402
Revenue per day             $     143.63                  $     147.39
Cost of service per day     $     75.40                   $     75.79
Average length of stay            99                            95




                            For the Six-Month Periods Ended June 30,
                            2013                          2012
Financial Information
(in millions):
Medicare                    $     122.9                   $     132.9
Non-Medicare                     7.5                         7.7       
                                                          
Net service revenue               130.4                         140.6
Cost of service                  68.9                        73.1      
                                                          
Gross margin                      61.5                          67.5
Other operating                  37.4                        36.0      
expenses
                                                          
Operating income            $     24.1                   $     31.5      
                                                          
Key Statistical Data:
Same store Medicare               (8         %)                 20        %
revenue growth (1)
Hospice Admits                    9,528                         9,589
Average daily census              4,973                         5,248
Revenue per day             $     144.84                  $     147.29
Cost of service per day     $     76.30                   $     76.45
Average length of stay            101                           93

(1) Same store Medicare revenue growth is the percent increase in our Medicare
revenue for the period as a percent of the Medicare revenue of the prior
period.






AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURE TO GAAP FINANCIAL STATEMENTS
(Amounts in thousands)
(Unaudited)

Earnings From Continuing Operations Before Interest, Taxes, Depreciation and
Amortization (“EBITDA”) and Adjusted EBITDA

                     For the Three-Month Periods    For the Six-Month Periods
                    Ended                         Ended
                     June 30,                       June 30,
                     2013            2012          2013            2012
Net income from
continuing
operations           $  2,331         $  7,903      $  5,501         $  14,716
attributable to
Amedisys, Inc.
Add:
Provision for           1,566            5,666         3,260            10,530
income taxes
Interest expense,       719              1,974         1,814            4,034
net
Depreciation and       11,674         9,678        21,621         19,515
amortization
                                                                     
EBITDA (1)           $  16,290       $  25,221     $  32,196       $  48,795
                                                                     
Add:
Exit activity           3,855            —             3,855            —
costs (2)
Gain on sale of         (357    )        —             (357    )        —
care centers
Intangible              (2,286  )        —             (2,286  )        —
write-off
Legal fees             1,584          1,406        3,587          5,113
(investigations)
                                                                     
Adjusted EBITDA      $  19,086       $  26,627     $  36,995       $  53,908
(3)



Adjusted Net Income From Continuing Operations Attributable to Amedisys, Inc.:

                     For the Three-Month Periods    For the Six-Month Periods
                     Ended                          Ended
                     June 30,                       June 30,
                     2013             2012          2013             2012
Net income from
continuing
operations           $  2,331         $  7,903      $  5,501         $  14,716
attributable to
Amedisys, Inc.
Add:
Exit activity           2,332            —             2,332            —
costs (2)
Gain on sale of         (216    )        —             (216    )        —
care centers
Legal fees             959            823          2,170          2,991
(investigations)
                                                                     
Adjusted net
income from
continuing
operations           $  5,406        $  8,726      $  9,787        $  17,707
attributable to
Amedisys, Inc.
(4)



Adjusted Net Income From Continuing Operations Attributable to Amedisys, Inc.
per Diluted Share:

                     For the Three-Month Periods    For the Six-Month Periods
                     Ended                          Ended
                     June 30,                       June 30,
                     2013             2012          2013             2012
Net income from
continuing
operations
attributable to      $  0.07          $  0.26       $  0.17          $  0.49
Amedisys, Inc.
common
stockholders per
diluted share
Add:
Exit activity           0.08             —             0.08             —
costs (2)
Gain on sale of         (0.01   )        —             (0.01   )        —
care centers
Legal fees             0.03           0.03         0.07           0.10
(investigations)
                                                                     
Adjusted net
income from
continuing
operations
attributable to      $  0.17         $  0.29       $  0.31         $  0.59
Amedisys, Inc.
common
stockholders per
diluted share (5)

(1) EBITDA is defined as net income from continuing operations attributable to
Amedisys, Inc. before provision for income taxes, net interest expense, and
depreciation and amortization. EBITDA should not be considered as an
alternative to, or more meaningful than, income before income taxes, cash flow
from operating activities, or other traditional indicators of operating
performance. This calculation of EBITDA may not be comparable to a similarly
titled measure reported by other companies, since not all companies calculate
this non-GAAP financial measure in the same manner.

(2)Exit activity costs of $3.8 million ($2.3 million net of tax or $0.08 per
diluted share) include charges of $2.3 million in depreciation and
amortization expense related to the write-off of intangible assets, $0.8
million in other general and administrative expenses related to lease
termination costs and $0.7 million in salaries and benefits related to
severance costs during the three-month period ended June30, 2013.

(3)Adjusted EBITDA is defined as net income from continuing operations
attributable to Amedisys, Inc. before provision for income taxes, net interest
expense, depreciation and amortization plus exit activity costs, the gain on
sale of care centers and legal fees associated with investigations. Adjusted
EBITDA should not be considered as an alternative to, or more meaningful than,
income before income taxes, cash flow from operating activities, or other
traditional indicators of operating performance. This calculation of adjusted
EBITDA may not be comparable to a similarly titled measure reported by other
companies, since not all companies calculate this non-GAAP financial measure
in the same manner.

(4)Adjusted net income from continuing operations attributable to Amedisys,
Inc. is defined as net income from continuing operations attributable to
Amedisys, Inc. plus exit activity costs, the gain on sale of care centers, and
legal fees associated with investigations. Adjusted net income from continuing
operations attributable to Amedisys, Inc. should not be considered as an
alternative to, or more meaningful than, income before income taxes, cash flow
from operating activities, or other traditional indicators of operating
performance. This calculation of adjusted net income from continuing
operations attributable to Amedisys, Inc. may not be comparable to a similarly
titled measure reported by other companies, since not all companies calculate
this non-GAAP measure in the same manner.

(5)Adjusted net income from continuing operations attributable to Amedisys,
Inc. common stockholders per diluted share is defined as diluted earnings from
continuing operations per share plus the earnings per share effect of exit
activity costs, the gain on sale of care centers and legal fees associated
with investigations. Adjusted net income from continuing operations
attributable to Amedisys, Inc. common stockholders per diluted share should
not be considered as an alternative to, or more meaningful than, income before
income taxes, cash flow from operating activities, or other traditional
indicators or operating performance. This calculation of adjusted net income
from continuing operations attributable to Amedisys, Inc. common stockholders
per diluted share may not be comparable to a similarly titled measure reported
by other companies, since not all companies calculate this non-GAAP financial
measure in the same manner.




Contact:

Amedisys, Inc.
Investor Contact:
Tom Dolan, 225-292-3391
Senior Vice President, Finance and Treasurer
tom.dolan@amedisys.com
or
Media Contact:
Jacqueline Chen Valencia, 225-299-3688
Senior Vice President – Marketing & Communications
jacqueline.chen@amedisys.com